Products

Unblind

Stop investing blind. Get a free audit of your trading decisions.

unblind.io Finance / Investing & Trading

AI Benchmark
Desktop
Mobile
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
$9.72/mo
Lower than 75% of peersNiche median $19/mo
Creators
Luis Diogo
No social account linked
Launched
2y ago
2024-04-26 · Est.

Traffic

Monthly visitsData through Oct 2026

Marketing moves

Launches, search & content, referrals, promotions

  • New product launchLaunch

    Apr 26, 2024 · 2y agoWebsite

Traffic sources

Oct 2026

Traffic breakdown

Channels

No data yet

Countries

No data yet

Search

Domain authority —Domain registered 2024-04-26

No search keyword data for this website yet.

Traffic data: Vaneform

Pricing

Free
€0
Eye Opener
€9 per month
Naked Truth
€19 per month
Ultimate Unblind
€39 per month

Trial: None · Observed 2026-11-04 · Pricing page

Entry price $9.72/mo, Lower than 75% of peers; “Investing & Trading” median is $19/mo.View pricing benchmark

Pages & changes

Tracked since 2026-08-08

Key pages

Weekly snapshots
app.unblind.io/ Snapshot 2026-11-04

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much does Unblind cost?
Free: €0; Eye Opener: €9 per month; Naked Truth: €19 per month; Ultimate Unblind: €39 per month. Observed 2026-11-04. Check the source for current billing terms, usage limits and taxes.Source
How much website traffic does Unblind get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is Unblind and what platforms does it support?
Unblind is catalogued under Investing & Trading: Stop investing blind. Get a free audit of your trading decisions.. Supported platforms: Web.

Related products in this category

Finance / Investing & Trading

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.